Table 2.
Risk for stent thrombosis among clopidogrel-treated patients in major meta-analyses
| Ref. | Year | Patient population in entire meta-analysis | Sample size (stent thrombosis analysis) | CYP2C19 genotype relative risk for stent thrombosisa |
|---|---|---|---|---|
| Hulot et al. 9 | 2010 | Established CAD | 4,905 | *1*2: 3.34 (1.84–5.93) |
| *2*2: 4.68 (1.55–14.11) | ||||
| *2 carrier: 3.45 (2.14–5.57) | ||||
|
| ||||
| Mega et al.7 | 2010 | Aggressively managed CAD patients | 6,094 | *1*2: 2.67 (1.69–4.22) |
| *2*2: 3.97 (1.75–9.02) | ||||
| *2 carrier: 2.81 (1.81–4.37) | ||||
|
| ||||
| Bauer et al.10 | 2011 | Established CAD | 19,328 | *2 carrier: 1.77 (1.31–2.40) |
|
| ||||
| Holmes et al.2 | 2011 | Unselectedb | 16,008 | *2 carrier: 1.75 (1.50–2.03) |
CAD, coronary artery disease.
a
The symbol *2 can refer to any CYP2C19 loss-of-function allele. See text for details.
b
Meta-analysis excluded studies with stent thrombosis as primary end point.